Abstracts tagged "Clinical practice guidelines"

Abstract Number: 1402 • ACR Convergence 2024
Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection
Jahan Marcu¹, Philip Molloy², Kayla Pray³ and Teresa Simon⁴, ¹Marcu Enterprises/ Physicians Research Center, Jersey City, NJ, ²Physicians Research Center,LLC, Carver, MA, ³Physicians Research Center,LLC, Farmingdale, NJ, ⁴Physicians Research Center,LLC, Toms River, NJ
Background/Purpose: Cannabis and its derivatives are increasingly integrated into treatments for rheumatic diseases, yet there is a significant lack of evidence and systematic data collection…
Abstract Number: 1414 • ACR Convergence 2024
Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations
Robert Fox¹, Anahita Deboo², Matthew Baker³, Stamatina Danielides⁴, Eduardo de Sousa⁵, Julie Frantsve Hawley⁶, Brent Goodman⁷, Katherine Hammitt⁶, Jennifer King⁸, Matt Makara⁶, Steven Mandel⁹, Ghaith Noaiseh¹⁰, Pantelis Pavlakis¹¹, George Sarka¹², Arun Varadhachary¹³, Daniel Wallace¹⁴, Robert Hal Scofield¹⁵, Nancy Carteron¹⁶ and Steven Carsons¹⁷, ¹Rheumatology Clinic, San Diego, CA, ²Temple University, Philadelphia, ³Stanford University, Menlo Park, CA, ⁴Vcu, Glen Allen, VA, ⁵Mercy, Moore, OK, ⁶Sjogren's Foundation, Reston, VA, ⁷Mayo Clinic, Scottsdale, AZ, ⁸UCLA, Los Angeles, CA, ⁹Hofstra, Hempstead, ¹⁰University of Kansas Medical Center, Kansas City, KS, ¹¹Hospital for Special Surgery, New York, NY, ¹²UCLA, Laguna Hills, CA, ¹³Washington University in St. Louis, St. Louis, MO, ¹⁴Cedars Sinai Medical Center, Studio City, CA, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of California, Berkeley & San Francisco, Angwin, CA, ¹⁷NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Peripheral Nervous System (PNS) manifestations occur frequently in Sjögren’s disease and can encompass mononeuropathy, polyneuropathy, and autonomic neuropathy. Guidance is needed for rheumatologists, neurologists,…
Abstract Number: 1501 • ACR Convergence 2024
Retrospective Cohort Study Identifying Pulmonary Complications in a Cohort of Patients with Systemic Lupus Erythematosus
Jessica Johnson¹, Chao Zhang² and Emily Littlejohn³, ¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ²Cleveland Clinic, Cleveland Heights, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multi organ involvement. One of the most common manifestations is pulmonary disease with a…
Abstract Number: 1949 • ACR Convergence 2024
Implementation of Pharmacist-Led Comprehensive Medication Management for Puerto Ricans with Rheumatic Diseases
Ileana Rodriguez Nazario, Kyle Melin and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Comprehensive Medication Management (CMM) is a standardized intervention provided by clinical pharmacists that uses subjective and objective patient information to create a plan to…
Abstract Number: 2017 • ACR Convergence 2024
Race, Ethnicity, and Rheumatology Care Predict Long-term Urate-Lowering Treatment Persistence Following a Treat-to-Target Intervention in a Large, Multicenter Randomized Trial
Samantha Kohn¹, Harlan Sayles¹, Lindsay Helget¹, Bryant England¹, Punyasha Roul², Joshua Qu¹, Jeff Newcomb¹, Bridget Kramer¹, Michael Duryee¹, Anne Davis-Karim³, Mary Brophy⁴, Ryan Ferguson⁴, Michael Pillinger⁵, Tuhina Neogi⁶, Paul Palevsky⁷, Hongsheng Wu⁴, James O'Dell¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³Veterans Affairs, Albuquerque, NM, ⁴Veterans Affairs, Boston, MA, ⁵New York University Grossman School of Medicine, New York,, NY, ⁶Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁷Veterans Affairs, Pittsburgh, PA
Background/Purpose: Gout management guidelines endorse treat-to-target (T2T) urate lowering therapy (ULT) to achieve and maintain serum urate (sUA) < 6.0 mg/dl. While T2T ULT interventions…
Abstract Number: 2162 • ACR Convergence 2024
Exploring Barriers to Rheumatoid Arthritis Treatment Changes: Insights into Patient Concerns
Nicholas McCormick¹, Jeffrey Curtis², Amy Mudano³, Shilpa Venkatachalam⁴, Kelly Gavigan⁵, Fenglong xie⁶, Patrick Stewart⁷ and Kimberly Garza¹, ¹Auburn University, Auburn, AL, ²Illumination Health, Birmingham, AL, ³Illumination Health, Hoover, AL, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁷Illumination Health, Vero Beach, AL
Background/Purpose: People with rheumatoid arthritis (RA) often hesitate to adjust their treatment due to concerns about medication risks and benefits. This study investigates RA patients'…
Abstract Number: 2304 • ACR Convergence 2024
Differential Diagnosis of Sjogren’s vs Non-Sjogren’s Dry Eye
Esen Akpek¹, Ian Saldanha², Pineal Bareamichael² and Michael Lin³, ¹Wilmer Eye Institute, JHU, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dry Eye Disease (DED) is a common multifactorial condition that significantly impacts patient quality of life. The etiology of DED is complex, involving tear…
Abstract Number: 2409 • ACR Convergence 2024
Adherence to EULAR Recommendations and Sub Optimal Management of Systemic Lupus Erythematosus in a Network of Community-Based Rheumatology Practices in the United States
Jeffrey Curtis¹, Emily Holladay², Amy Mudano³, Emily Smitherman⁴, Fenglong xie⁵, Shanette G. Daigle⁶, Yujie Su³, Mawuena Binka⁷, Gelareh Atefi⁸, Rana Muhammad Qasim Khan⁹ and Tope Olufade¹⁰, ¹Illumination Health, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Illumination Health, Hoover, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁶Foundation for Advancing Science, Technology, Education, and Research, Birmingham, ⁷BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁸AstraZeneca, Media, PA, ⁹BioPharmaceuticals Medical, AstraZeneca, Wilmington, ¹⁰AstraZeneca, Wilmington, DE
Background/Purpose: Despite new developments in systemic lupus erythematosus (SLE) treatment and treatment guidelines, the clinical management of SLE is often sub-optimal. We aimed to describe…
Abstract Number: 0214 • ACR Convergence 2024
Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Justin Dunn¹, Scott Matson², Michael George³, Yangyuna Yang¹, Punyasha Roul⁴, Jorge Rojas⁵, grant Cannon⁶, Sauer brian⁷, Jeffrey Curtis⁸, Joshua Baker³, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Kansas, Kansas City, MO, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵Seattle VA, Mexico, Mexico, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸University of Alabama at Birmingham, Hoover, AL
Background/Purpose: The American College of Rheumatology (ACR) and American College of Chest Physicians (CHEST) recently released clinical practice guidelines for the treatment of RA-interstitial lung…
Abstract Number: 2619 • ACR Convergence 2024
Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients
Tali Eviatar¹, Iftach Sagy², Elad Brav², Amir Bieber³, Victoria Furer⁴ and Ori Elkayam⁵, ¹Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, ²Soroka Medical Cenrter, beer sheva, Israel, ³Emek Medical Center, Clalit Health Services, Raanana, Israel, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
Abstract Number: 0537 • ACR Convergence 2024
Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Knkush Hakobyan¹, Talar Acob², Mesrop Aleksanyan³, Tigran Kakhktsyan³, Omar Jumaah³ and Sajina Prabhakaran⁴, ¹Capital Health medical center, Princeton, NJ, ²College of medicine-university of Baghdad, Plainsboro Township, NJ, ³Capital Health Medical Center, Trenton, ⁴Capital health Rheumatology specialists, Newtown, PA
Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
Abstract Number: 2687 • ACR Convergence 2024
Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts
Michael Macklin¹, Iazsmin Bauer Ventura¹ and Dinesh Khanna², ¹University of Chicago, Chicago, IL, ²University of Michigan, Ann Arbor, MI
Background/Purpose: The therapeutic options for systemic sclerosis-associated interstitial lung disease (SSc-ILD) have evolved rapidly, with recent guidelines released by the ACR and American Thoracic Society…
Abstract Number: 0657 • ACR Convergence 2024
Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis
Jagan K L¹, Augustine Jose², Vishnupriya G¹, Dellan S¹, Dhanush S¹, Samskruthi Reddy Tokala¹, Bhavana Mashetty¹, Chengappa Kavadichanda³, Sachith ganapathy¹, Aishwarya Gopal⁴, Rithik Roshan¹, Sareddy Sai vignesh Reddy¹, Sonal Mehra⁵, Molly Thabah¹ and Vir Singh Negi⁶, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁵JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
Abstract Number: 0692 • ACR Convergence 2024
Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Laura Sierra Herranz⁴, Javier Juan Garcia⁴, Ivan Castellvi Barranco⁵ and elvira Diez álvarez⁴, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, Leon, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is one of the leading causes of morbidity and mortality. Recently,…
Abstract Number: 0859 • ACR Convergence 2024
Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kylie Carlson¹, Mahmut Kaymakci², Sebastian E. Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].